UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~June 71, 2026

PRAXIS PRECISION MEDICINES, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-39620	47-5195942
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Praxis Precision Medicines, Inc.

99 High Street, 30th Floor

Boston, Massachusetts 02110

(Address of principal executive offices, including zip code)

(617) 300-8460

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trade

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

PRAX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 28.0201. Other ~~Results of Operations and Financial Condition~~Events.

On ~~May 7~~June 1, 2026, Praxis Precision Medicines, Inc. (the “Company”) announced results from the Phase 2/3 POWER1 study evaluating vormatrigine in patients with focal onset seizures (“FOS”). The POWER1 study in highly refractory patients with FOS did not meet its ~~financial~~primary ~~results~~success ~~for~~measure. The secondary measure, the ~~quarter~~50% ~~ended~~response ~~March 31~~rate, ~~2026.~~was Amet ~~copy~~and ofseizure reduction during the ~~press~~second ~~release~~half ~~containing~~of ~~these~~the ~~announcements~~study ison ~~furnished~~higher asdose ~~Exhibit~~(30 99mg) was more pronounced.1 toVormatrigine ~~this~~was ~~Current~~generally ~~Report~~well-tolerated onand ~~Form~~adverse 8event-Krelated (discontinuations were less than 10%. Approximately 90% of patients from the ~~“Current~~vormatrigine ~~Report”)~~arm transitioned to and remain in the open label extension study.

~~Item~~The ~~7.01.~~Company ~~Regulation~~is FDpausing ~~Disclosure~~enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications.

OnForward-Looking May 7, 2026, the Company updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available in the “Investors + Media” portion of the Company’s website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.2 to this Current Report.Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the clinical development of vormatrigine. The ~~information~~forward-looking statements included in this Current Report ~~under~~on ~~Items~~Form ~~2.02~~8-K ~~and~~are ~~7.01,~~subject ~~including~~to ~~Exhibit~~a ~~99.1~~number ~~and~~of ~~Exhibit~~risks, ~~99.2~~including, ~~attached~~without ~~hereto~~limitation, isuncertainties ~~intended~~inherent toin beclinical ~~furnished~~trials and ~~shall~~other ~~not~~risks beas ~~deemed~~described ~~“filed”~~in the Company’s Annual Report on Form 10-K for ~~purposes~~the ofyear ~~Section~~ended 18December of31, 2025 and other filings with the Securities and Exchange ~~Act~~Commission. ofThese ~~1934,~~statements asare ~~amended~~based (only on facts currently known by the ~~“Exchange~~Company ~~Act”),~~and orspeak ~~otherwise~~only ~~subject~~as toof the ~~liabilities~~date of ~~that~~this ~~section,~~Current ~~nor~~Report ~~shall~~on itForm be8-K. ~~deemed~~As ~~incorporated~~a byresult, ~~reference~~you inare ~~any~~cautioned ~~filing~~not ~~under~~to rely on these forward-looking statements and the ~~Securities~~Company ~~Act~~undertakes ofno ~~1933,~~obligation asto ~~amended,~~publicly update or ~~the~~revise ~~Exchange~~any ~~Act~~forward-looking statement, ~~except~~whether as ~~expressly~~a ~~set~~result ~~forth~~of bynew ~~specific~~information, ~~reference~~future indevelopments ~~such~~or ~~filing~~otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.						Description
99.1						Press Release, dated May 7, 2026
99.2						Praxis Precision Medicines, Inc. May 2026 Corporate Presentation
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRAXIS PRECISION MEDICINES, INC.
Date: May 7, 2026	By:	/s/ Marcio Souza
Date: June 1, 2026	By:	/s/ Marcio Souza
		Marcio Souza
		Chief Executive Officer

Filing Compare · Praxis Precision Medicines, Inc.